Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Gynecologic 1Endocrine 1CNS 1

Conditions

Stomach Neoplasms 2Gastrointestinal Stromal Tumors 2Colonic Neoplasms 2Vipoma 1Somatostatinoma 1Rectal Neoplasms 1Pseudomyxoma Peritonei 1Pheochromocytoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms, Unknown Primary 1Neoplasms 1Insulinoma 1Glucagonoma 1Gastrinoma 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1Appendiceal Neoplasms 1

Interventions

Gemcitabine 9pembrolizumab 7Irinotecan 5Docetaxel 4Cisplatin 4Carboplatin 4Capecitabine 4Albumin-Bound Paclitaxel 4Paclitaxel 3Oxaliplatin 3Leucovorin 3Cyclophosphamide 3Cetuximab 3130-nm albumin-bound paclitaxel 3pazopanib 2palbociclib 2liposomal doxorubicin 2entrectinib 2alectinib 2Vinorelbine 2Trastuzumab 2Taxes 2Radiosurgery 2Oncolytic Virotherapy 2Observation 2Ipilimumab 2Fluorouracil 2Fluorodeoxyglucose F18 2Filgrastim 2Erlotinib Hydrochloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Floxuridine × Sarcoma × Clear all
NCT00005860 2011-04-26

Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum

National Cancer Institute (NCI)

Phase 1 Completed
CNSEndocrineGastrointestinalGynecologicSarcoma

Appendiceal Neoplasms, Bile Duct Neoplasms, Colonic Neoplasms, Vipoma, Fallopian Tube Neoplasms, Gallbladder Neoplasms, Glucagonoma, Carcinoma, Hepatocellular, Insulinoma, Neoplasms, Neoplasms, Unknown Primary, Neuroblastoma, Pancreatic Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Stomach Neoplasms, Gastrinoma, Carcinoma, Islet Cell, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡